Loading company…
Medgencell.com is a Chengdu biotech firm providing cell therapy R&D, with a CRISPR-edited T-cell product in Phase I trials.
Established in 2015 and based in Chengdu, China, Medgencell.com provides precision cell therapy research, development and services. Its self-developed CRISPR gene-edited T-cell product has completed Phase I clinical trials at West China Hospital of Sichuan University, and its technologies cover tumour cell biotherapy and stem cell regenerative medicine. In January 2025 it closed a strategic investment from Zhongguancun Development Venture, which it plans to use to develop cell-based therapies.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in